Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-04-23 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司薪酬与考核委员会工作细则（2024.04）
Governance Information Classification · 95% confidence The document is titled '董事会薪酬与考核委员会工作细则' which translates to 'Board Remuneration and Assessment Committee Working Rules'. It details the structure, responsibilities, and procedures of the board's remuneration and assessment committee, including how remuneration plans are proposed, reviewed, and approved. There is no financial data, no report of financial results, no voting results, no announcement of a report, and no legal or regulatory filing. The document is a governance-related internal rules document about board and management compensation and assessment policies. Therefore, it fits best under Governance Information (CGR). The document length is 2900 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2024-04-23 Chinese
北京双鹭药业股份有限公司独立董事钱令嘉2023年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director of the company, describing their duties, attendance at meetings, committee work, communication with auditors and shareholders, and overall evaluation for the year 2023. It includes information about board activities, audit committee involvement, and governance oversight. The content focuses on the director's management and board-related responsibilities rather than financial results or audit opinions alone. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is not a simple announcement or certification but a substantive management/board report. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities.
2024-04-23 Chinese
北京双鹭药业股份有限公司独立董事工作制度（2024.04）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' (Independent Director Work System) and contains detailed governance rules and procedures related to the role, qualifications, duties, and protections of independent directors at Beijing SL Pharmaceutical Co., Ltd. It references relevant laws, regulations, and stock exchange rules, and outlines internal governance practices. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and internal rules for board members, specifically independent directors. Therefore, this document fits the category of Governance Information (CGR). The document length (9630 characters) and detailed content confirm it is a full governance policy document, not a brief announcement or certification.
2024-04-23 Chinese
北京双鹭药业股份有限公司董事会战略与投资决策委员会工作细则（2024.04）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic and Investment Decision Committee Work Rules" of Beijing SL Pharmaceutical Co., Ltd., dated April 2024. It details the committee's composition, responsibilities, decision-making procedures, meeting rules, and governance structure. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, no earnings information, and no report publication announcement. The document is a governance-related internal rules document describing the board committee's structure and functions. Therefore, it fits the category of Governance Information (CGR). The document length is 2272 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2024-04-23 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2023 年年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management statements, and comprehensive business and financial information for the fiscal year 2023 (January 1 to December 31). There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-23 Chinese
北京双鹭药业股份有限公司关于职工代表大会选举职工监事的决议公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of an employee representative supervisor to the company's supervisory board. It includes details about the election meeting, the elected individual's background, and compliance with relevant laws. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses on board/management information, specifically about a supervisory board member election. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2024-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.